and its value as a prognostic biomarker in patients with metastatic nonesmall cell lung cancer (NSCLC). Method: The clinical chart of consecutive metastatic NSCLC patients treated in Edgardo Rebagliati Martins National Hospital, Lima-Perú, between July 2014 and December 2015, were retrospectively evaluated. Epidemiological, disease and extension data were collected, as well as white cell differential before either, definitive treatment or best supportive care. Survival analysis was performed using log-rank test, Kaplan-Meier method and Cox regression analysis using NLR cut-off point of 5 as previously reported. R language was used for statistical analysis. Results: Ninety clinical charts of advanced NSCLC patients were evaluated, of which 36 cases were considered for final analysis. The mean age was 69 years (SD 11.9). Twenty-three patients were female (63.9%), 28 were nonsmokers (77.8%) and 32 had adenocarcinoma (88.9%), median NLR was 3.4. The median overall survival (OS) was 7.95 months. Median OS for patients with NLR 3 5 was 3.97 months vs. 12.07 months for NLR < 5 (p ¼ 0.0041). Cox analysis for NLR < 5 was performed, adjusting with variables such as age (HR: 0.27, p ¼ 0.008), gender (HR: 0.30, p ¼ 0.012) and systemic treatment (HR: 0.34, p ¼ 0.038). Finally, we performed multivariate analysis adjusting for all variables that potentially can influence in mortality such as age, gender, systemic treatment and metastatic sites and we found HR 0.27 for NLR < 5 (95%CI 0.09 -0.84, p ¼ 0.024). Conclusion: NLR < 5 was statistically associated with better overall survival. Multivariate analysis adjusted by age, gender, systemic treatment and metastatic compromise, was able to predict better overall survival, with a hazard ratio of 0.27 for NLR < 5. The retrospective design and limitations of our study only allow us to generate the hypothesis that NLR < 5 could be an easy and inexpensive marker of better survival in metastatic lung cancer patients and support design of larger and prospective trials. Background: Lung cancer is the most common cause of cancer death worldwide, as detection of the disease only occurs in advanced stages. The heterogeneity of lung tumor cells suggests that these may originate from multipotent cells. Several studies suggest that tumor-initiating cells (cancer stem cells, CSCs) may be the cause of tumor growth, metastasis and resistance to conventional therapies leading to tumor recurrence. The lack of specific markers for CSC detection hinders the use of these cells in determining disease prognosis in clinical practice. Thus, the objective of this project is the development of DNA aptamers for selective identification of the molecular signature of lung CSC. Method: Using A549 human lung cancer cells as target to perform the isolation of DNA aptamers from a random library through the cell-SELEX (Systematic Evolution of Ligands by EXponential enrichment) it was possible to isolate stem-like cells by cell sorting using fluorescence-tagged aptamer. To eliminate DNA aptamers binding to common epitopes between different cell types, blood cells were used as target in subtractive-SELEX. To analyze the affinity and specificity of selected aptamers, we used conventional analytical technologies (cytometry, microscopic analysis). Results: After seven cycles of cell-SELEX we obtained a pool of aptamers able to identify CD90 + lung cancer cells. CD has been described as a marker for cancer stem cells. The aptamers were divided into families based on homology between sequences. Eight aptamers were identified, whose affinity and specificity are currently being analyzed. The results of in vitro tumorigenesis assays suggest that aptamer-positive cells increase their capacity for invasion and migration. Background: The present evidence refers to the potential role of tumor infiltrating lymphocytes (TIL) in determining the survival of nonesmall cell lung cancer (NSCLC). TILs are generally determined using semiquantitative subjective methods. While several studies have researched the prognosis of different subtypes of TIL, the data are limited to the co-expression of TIL subpopulations and their clinical relevance. Primary objective: to identify subgroups of patients with NSCLC, according to the status of lymphocyte infiltration in the tissue sample, classified as mild, moderate, severe or absent, and research its relationship to progression-free survival (PFS) and overall survival (OS). Method: The medical records of 480 patients with nonesmall cell lung cancer stages IIIB and IV were analyzed. 166 patients out of 480 met the selection criteria. The tumor-associated lymphoid infiltrates were descriptively classified as mild, moderate, severe or absent, based on morphological observation only. The relationship with the clinicopathological variables were assessed by Chi-square analysis, and the association with overall survival was performed using the Cox proportional hazards analysis model. The Kaplan-Meier method was used to compare survival curves. Results: 56% of patients had been diagnosed with adenocarcinoma, 39% with squamous cell carcinoma, and only 5% had undifferentiated carcinoma histology. 70% of patients were male, and 82% of the patients were smokers. Regarding PFS in all patients, those with an intense lymphocyte infiltrate had higher PFS (9.66 months) compared to moderate (6.22 months) and minor (5.66 months). Also the OS of all patients was higher in those who presented severe lymphocyte infiltrate (17.44 months), followed by those with infiltration moderate (10.08 months) and patients with lower OS were patients with mild infiltrate (9.17 months). As adenocarcinoma patients, those with an intense lymphocyte infiltrate had higher OS and PFS; 15.28 and 9.25 months, respectively. Compared to patients with moderate infiltrate, 10.07 and 6.25 months, patients with mild infiltrate, 8.25 and 5.55 months. Only OS different values were statistically significant (p ¼ 0.019). Conclusion: Patients whose pathology reports showed an intense inflammatory infiltrate increased pfs and had higher OS. These differences were statistically significant only for OS in patients with adenocarcinoma (p ¼ 0.019). We observed that those with a greater number of lymphocytes in the tumor tissue samples showed a higher OS. However, we are performing prospective studies prospective with a larger number of patients to draw conclusions with greater statistical significances. Hospital Beatriz Ângelo, Lisbon/PT Background: Lung cancer is the leading cause of cancer-related mortality worldwide and its incidence continues to rise. Overall survival remains low, hence the importance of accurate staging and approach. When indicated, surgical resection remains the gold standard. Our aim was to compare outcomes in surgical patients of a district hospital with those described in the literature. Method: Data was collected retrospectively from March 2012 to December 2017 and analyzed using MS Excel. All patients were evaluated in a multidisciplinary board. Patients operated for diagnostic purpose were excluded. Results: Out of 488 patients diagnosed with lung cancer, 101 surgeries were performed, regarding 88 patients. Mean age was 63,5 (±9,4) and 68% were male. Smoking habits were present in 77% of patients, COPD and enphysema in 19%, diabetes mellitus in 14% and previous lung cancer in 1 patient. Adenocarcinoma (71%) was the most frequent tumor. Concerning pathological stage, 54% of patients were stage IA or IB. 23% were operated after neoadjuvant treatment. 71% of patients were submitted to lobectomy with systematic lymph node dissection and 14% to wedge resection. 41% of cases were approached using VATS techniques. Adjuvant chemotherapy, radiotherapy and chemotherapy plus radiotherapy were indicated in 34%, 4% and 9% of cases, respectively.
Background: Lung cancer is the most common cause of cancer death worldwide, as detection of the disease only occurs in advanced stages. The heterogeneity of lung tumor cells suggests that these may originate from multipotent cells. Several studies suggest that tumor-initiating cells (cancer stem cells, CSCs) may be the cause of tumor growth, metastasis and resistance to conventional therapies leading to tumor recurrence. The lack of specific markers for CSC detection hinders the use of these cells in determining disease prognosis in clinical practice. Thus, the objective of this project is the development of DNA aptamers for selective identification of the molecular signature of lung CSC. Method: Using A549 human lung cancer cells as target to perform the isolation of DNA aptamers from a random library through the cell-SELEX (Systematic Evolution of Ligands by EXponential enrichment) it was possible to isolate stem-like cells by cell sorting using fluorescence-tagged aptamer. To eliminate DNA aptamers binding to common epitopes between different cell types, blood cells were used as target in subtractive-SELEX. To analyze the affinity and specificity of selected aptamers, we used conventional analytical technologies (cytometry, microscopic analysis). Results: After seven cycles of cell-SELEX we obtained a pool of aptamers able to identify CD90 + lung cancer cells. CD has been described as a marker for cancer stem cells. The aptamers were divided into families based on homology between sequences. Eight aptamers were identified, whose affinity and specificity are currently being analyzed. The results of in vitro tumorigenesis assays suggest that aptamer-positive cells increase their capacity for invasion and migration. Background: The present evidence refers to the potential role of tumor infiltrating lymphocytes (TIL) in determining the survival of nonesmall cell lung cancer (NSCLC). TILs are generally determined using semiquantitative subjective methods. While several studies have researched the prognosis of different subtypes of TIL, the data are limited to the co-expression of TIL subpopulations and their clinical relevance. Primary objective: to identify subgroups of patients with NSCLC, according to the status of lymphocyte infiltration in the tissue sample, classified as mild, moderate, severe or absent, and research its relationship to progression-free survival (PFS) and overall survival (OS). Method: The medical records of 480 patients with nonesmall cell lung cancer stages IIIB and IV were analyzed. 166 patients out of 480 met the selection criteria. The tumor-associated lymphoid infiltrates were descriptively classified as mild, moderate, severe or absent, based on morphological observation only. The relationship with the clinicopathological variables were assessed by Chi-square analysis, and the association with overall survival was performed using the Cox proportional hazards analysis model. The Kaplan-Meier method was used to compare survival curves. Results: 56% of patients had been diagnosed with adenocarcinoma, 39% with squamous cell carcinoma, and only 5% had undifferentiated carcinoma histology. 70% of patients were male, and 82% of the patients were smokers. Regarding PFS in all patients, those with an intense lymphocyte infiltrate had higher PFS (9.66 months) compared to moderate (6.22 months) and minor (5.66 months). Also the OS of all patients was higher in those who presented severe lymphocyte infiltrate (17.44 months), followed by those with infiltration moderate (10.08 months) and patients with lower OS were patients with mild infiltrate (9.17 months). As adenocarcinoma patients, those with an intense lymphocyte infiltrate had higher OS and PFS; 15.28 and 9.25 months, respectively. Compared to patients with moderate infiltrate, 10.07 and 6.25 months, patients with mild infiltrate, 8.25 and 5.55 months. Only OS different values were statistically significant (p ¼ 0.019). Conclusion: Patients whose pathology reports showed an intense inflammatory infiltrate increased pfs and had higher OS. These differences were statistically significant only for OS in patients with adenocarcinoma (p ¼ 0.019). We observed that those with a greater number of lymphocytes in the tumor tissue samples showed a higher OS. However, we are performing prospective studies prospective with a larger number of patients to draw conclusions with greater statistical significances. Hospital Beatriz Ângelo, Lisbon/PT Background: Lung cancer is the leading cause of cancer-related mortality worldwide and its incidence continues to rise. Overall survival remains low, hence the importance of accurate staging and approach. When indicated, surgical resection remains the gold standard. Our aim was to compare outcomes in surgical patients of a district hospital with those described in the literature. Method: Data was collected retrospectively from March 2012 to December 2017 and analyzed using MS Excel. All patients were evaluated in a multidisciplinary board. Patients operated for diagnostic purpose were excluded. Results: Out of 488 patients diagnosed with lung cancer, 101 surgeries were performed, regarding 88 patients. Mean age was 63,5 (±9,4) and 68% were male. Smoking habits were present in 77% of patients, COPD and enphysema in 19%, diabetes mellitus in 14% and previous lung cancer in 1 patient. Adenocarcinoma (71%) was the most frequent tumor. Concerning pathological stage, 54% of patients were stage IA or IB. 23% were operated after neoadjuvant treatment. 71% of patients were submitted to lobectomy with systematic lymph node dissection and 14% to wedge resection. 41% of cases were approached using VATS techniques. Adjuvant chemotherapy, radiotherapy and chemotherapy plus radiotherapy were indicated in 34%, 4% and 9% of cases, respectively.
Perioperative mortality was 0,9% (1 case) and 10,9% had complications, pneumonia being the most frequent. Mean follow-up time was 31 months (±16 Argentina enrolled 29 patients from three centers. At data cut-off (20 Oct 2017) 25 patients (78,1%) were still ongoing, 4 patients had died. Median follow up 3,3 months (0-8). The mean age was 59.6 years (35-91); 72,4% (21) were less than 65 years old; 82,8% females; 96,6% Caucasian; ECOG 0-1 65,5%, ECOG 2 20,7%. Stage IV 89,7%. Previous cancer therapies included gefitinib 37,9%, erlotinib 31% and afatinib 37,9%. 48,3% of the patients had received previous chemotherapy, 6,9% previous immunotherapy and 31% previous radiotherapy. Only patients with T790M positive were enrolled in this study, 27,6% (8) had tissue biopsy at progression; 65,5% (19) were diagnosed by plasma sample [FT1] [BP2] , 3,4% (1) by cytology and 3,4% (1) after bone marrow biopsy. The origin of the biopsy tissue was primary tumor in 87,5% and metastasis in 12,5%. T790M mutation was found in all the patients. T790M alone in 72,4% (21) and in combination with other EGFR mutations in 27,6% (8) [FT3] . The other EGFR mutations were exon 19 deletion 20,7%; exon 20 insertion 6,9% and L858R 6,9%. Testing methods: Roche Cobas 1; Qiagen Therascreen 16; Entrogen EGFR kit 3, sanger sequencing 1, ddPCR 7, unknown 1. Conclusion: We present real word evidence data of demographics and diagnostic patterns of patients beyond progression. Efficacy data is still immature and will be presented in subsequent interim analysis. Keywords: T790M EGFR, Advanced lung cancer, osimertinib, Astris Real Word Evidence Trial
